Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| RON-H52H9 | Human | Human RON / MSPR Protein, His Tag (MALS verified) |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Crizotinib | PF-1066; PF-2341066; PF-02341066; PF-002341066 | Approved | Pfizer Pharmaceuticals Ltd (China) | 赛可瑞, Xalkori | EU | Lymphoma, Large-Cell, Anaplastic | Pfizer Europe Ma Eeig | 2011-08-26 | Neuroblastoma; Neoplasm Metastasis; Neurilemmoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Lymphoma; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Ureteral Neoplasms; Hematologic Neoplasms; Urethral Neoplasms; Myofibroma; Prostatic Neoplasms, Castration-Resistant; Uveal melanoma; Multiple Myeloma; Urinary Bladder Neoplasms; Kidney Diseases; Neurofibromatosis 2; Neoplasms; Solid tumours | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Narnatumab | Eli Lilly And Company | Details | |||
| Glesatinib | 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265; MG-90265X; MGCD-265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
